Henlius Novel Anti PD-L1/TIGIT Bispecific Antibody Received Clinical Trial Approval in Australia
SHANGHAI, Nov. 25, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the filing of a clinical trial for HLX301, a Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, in Patients with locally advanced or metastatic solid tumours has been approved by the ...
2021 CSCO | Henlius will Release Four Oral Presentations of Two Upcoming Commercial Products: Novel anti-PD-1 mAb Serplulimab and Bevacizumab Biosimilar
SHANGHAI, Sept. 18, 2021 /PRNewswire/ -- The 24th Annual Meeting of Chinese Society of Clinical Oncology (CSCO) will be held online and in-person from 25th to 29th September 2021. In this meeting, Henlius will release 4 study results of 2 products to be commercialized, the novel anti-PD-1 mAb ser...
The NDA of Henlius Novel Anti-PD-1 mAb Serplulimab for First-Line Treatment of sqNSCLC Accepted by China's NMPA, Phase 3 MRCT Met its Primary Endpoint
SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of Serplulimab Injection (HLX10), a novel anti-PD-1 monoclonal antibody (mAb) independently developed by the company, in combination with carboplatin and albumin-bound ...
Henlius reports half-year (H1) 2021 results, outlines remarkable growth in commercialization and needs-driven innovation
SHANGHAI, Aug. 18, 2021 /PRNewswire/ -- Henlius (2696.HK) announced Half-Year (H1) results endedJune 30th, 2021, sharing the company's recent noteworthy progress and achievements. As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, affordable and innov...
